RxDoctor Payments DataLook up a doctor →

Scott Gauthreaux, MD

Retina Specialist · Lafayette, LANPI 1710942065

Payments from drug & device makers

$6,548in general payments, 2019–2025

Across 246 payments — averaging $26.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$2K
  • Alimera Sciences, Inc.$898
  • AbbVie$677
  • Eyepoint US, Inc.$549
  • Genentech USA, Inc.$452
  • Mallinckrodt Hospital Products Inc.$441
  • plus $2K from 13 others

What the payments were for

  • Food & beverage$6,24295%
  • Education$2143%
  • Entertainment$931%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,548 in reported general payments places this provider in the 70th percentile of 30 retina specialist providers in Louisiana.

See all retina specialist providers in Louisiana

Medicare billing

Part B allowed, 2024
$2,036,454
Medicare patients
919
Services billed
173,590

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Bromfenac Sodium43$6,535
Prednisolone Acetate155$6,490
IlevroNepafenac11$4,032
Difluprednate31$3,195
Methazolamide12$2,450
Travoprost21$2,258
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat126$2,164
Ketorolac Tromethamine57$1,871
Brimonidine Tartrate47$1,811
MoxifloxacinMoxifloxacin Hcl68$1,383
Diclofenac Sodium81$881
Latanoprost50$664
Acetazolamide ErAcetazolamide19$542
Atropine Sulfate12$395
Timolol Maleate44$332

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisIlevro$145$4,03211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 30 retina specialist providers in Louisiana.

Other retina specialist in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →